Squalene monooxygenase: a journey to the heart of cholesterol synthesis.

Cholesterol Cholesterol homeostasis Endoplasmic reticulum-associated degradation (ERAD) Squalene Squalene monooxygenase

Journal

Progress in lipid research
ISSN: 1873-2194
Titre abrégé: Prog Lipid Res
Pays: England
ID NLM: 7900832

Informations de publication

Date de publication:
07 2020
Historique:
received: 03 03 2020
revised: 21 04 2020
accepted: 24 04 2020
pubmed: 4 5 2020
medline: 12 1 2021
entrez: 4 5 2020
Statut: ppublish

Résumé

Squalene monooxygenase (SM) is a vital sterol synthesis enzyme across eukaryotic life. In yeast, it is a therapeutic target for treating certain fungal infections, and in mammals it is a rate-limiting enzyme that represents a key control point in the cholesterol synthesis pathway. SM introduces an oxygen atom to squalene, which becomes the signature oxygen of the hydroxyl group in cholesterol. Our knowledge of SM has advanced tremendously since its initial cloning and characterization. Early research developed mammalian SM inhibitors to target SM for cholesterol-lowering purposes. The substrate squalene has gained considerable interest for its health benefits and in nanomedicine for delivery of drugs. More recently, SM has been implicated as a key dysregulated component in certain cancers. In this review, we summarize our present knowledge of SM, focusing on the regulation of SM and the gene encoding it, SQLE. Furthermore, we offer insights into the role of SM across different organisms and its significance in human health and disease.

Identifiants

pubmed: 32360125
pii: S0163-7827(20)30013-8
doi: 10.1016/j.plipres.2020.101033
pii:
doi:

Substances chimiques

Cholesterol 97C5T2UQ7J
Squalene Monooxygenase EC 1.14.14.17

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101033

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None declared.

Auteurs

Ngee Kiat Chua (NK)

School of Biotechnology and Biomolecular Sciences, UNSW Sydney, Sydney, NSW 2052, Australia.

Hudson W Coates (HW)

School of Biotechnology and Biomolecular Sciences, UNSW Sydney, Sydney, NSW 2052, Australia.

Andrew J Brown (AJ)

School of Biotechnology and Biomolecular Sciences, UNSW Sydney, Sydney, NSW 2052, Australia. Electronic address: aj.brown@unsw.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH